1552-P: Preliminary Psychometric Properties of the Problem Areas in Diabetes-Child and Parent Short Form

Introduction and Objective: Diabetes distress (DD), the emotional burden associated with managing type 1 diabetes (T1D), affects both children and their parents. Guidelines recommend routine DD screening, yet lengthy measures hinder workflow integration. Shorter versions of the Parent Problem Areas in Diabetes-Child (PPAID-C) and Problem Areas in Diabetes-Child (PAID-C) may offer a practical solution. This study reports preliminary psychometric properties of newly developed short forms: PPAID-CSF and PAID-CSF. Methods: We selected items with the highest factor loadings from prior analyses of the full PPAID-C and PAID-C. In a new sample of school-age children and their parents, we assessed internal consistency (Cronbach’s α), test-retest reliability, and correlations with child and parent resilience, parent-reported adherence, and child glucose at baseline and 6-month follow-up. Results: 132 parent-child dyads participated (child age M= 10.23 ± 1.5 yrs, 50% boys; 91% mothers). Cronbach’s α was acceptable for the 3 item PAID-CSF (0.75) and for the 4 item PPAID-CSF (0.82). Test-retest reliability indicated good stability over 6 months (ICC≥ 0.77). Both short forms were negatively correlated with parent and child resilience across time points. PPAID-CSF correlated positively with child HbA1c, while PAID-CSF correlated negatively with adherence. Prospectively, higher PPAID-CSF predicted suboptimal glycemic outcomes (40% time in range and 60% time above range at 6 months), though neither form associated with concurrent CGM metrics. Conclusion: The PPAID-CSF and PAID-CSF demonstrated strong reliability and evidence of construct validity, supporting their potential for clinical and research use. These brief tools may facilitate routine DD screening without adding significant burden to care workflows. Future research should evaluate their responsiveness to change, establish clinically meaningful cut-points, and examine performance across diverse populations. Disclosure A. Monzon: None. S.R. Patton: Advisory Panel; Current; Glooko, Inc. J. Weissberg-Benchell: Consultant; Ended; Sanofi. M. Clements: Employee; Current; Glooko, Inc. Research Support; Ended; Dexcom, Inc., Abbott Diabetes. Funding National Institutes of Health (R01DK127493)